MA52970A - Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations - Google Patents

Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations

Info

Publication number
MA52970A
MA52970A MA052970A MA52970A MA52970A MA 52970 A MA52970 A MA 52970A MA 052970 A MA052970 A MA 052970A MA 52970 A MA52970 A MA 52970A MA 52970 A MA52970 A MA 52970A
Authority
MA
Morocco
Prior art keywords
psma
antibodies
bispecific
bispecific anti
Prior art date
Application number
MA052970A
Other languages
English (en)
Inventor
Lauric Haber
Aynur Hermann
Andrew J Murphy
Dimitris Skokos
Eric Smith
Erica Ullman
Janelle Waite
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA52970A publication Critical patent/MA52970A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA052970A 2018-06-21 2019-06-21 Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations MA52970A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862688227P 2018-06-21 2018-06-21
US201862781980P 2018-12-19 2018-12-19
US201862781930P 2018-12-19 2018-12-19
US201962815878P 2019-03-08 2019-03-08

Publications (1)

Publication Number Publication Date
MA52970A true MA52970A (fr) 2021-04-28

Family

ID=67297279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052970A MA52970A (fr) 2018-06-21 2019-06-21 Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations

Country Status (16)

Country Link
US (3) US11548947B2 (fr)
EP (1) EP3810282A1 (fr)
JP (2) JP7677796B2 (fr)
KR (2) KR20250156829A (fr)
CN (2) CN112351820B (fr)
AU (2) AU2019290198B2 (fr)
BR (1) BR112020025926A2 (fr)
CA (1) CA3104098A1 (fr)
CL (1) CL2020003285A1 (fr)
IL (2) IL279354B1 (fr)
MA (1) MA52970A (fr)
MX (1) MX419677B (fr)
MY (1) MY205387A (fr)
PH (1) PH12020552116A1 (fr)
SG (1) SG11202012729YA (fr)
WO (1) WO2019246514A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP3456700A1 (fr) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP3533473A3 (fr) 2013-11-14 2019-12-18 Endocyte, Inc. Composés pour la tomographie par émission de positrons
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
EP4107279A4 (fr) * 2020-02-18 2024-07-17 Endocyte, Inc. Procédé de traitement de cancers exprimant psma
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
KR20230042035A (ko) * 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
CA3192204A1 (fr) 2020-08-19 2022-02-24 Xencor, Inc. Anticorps anti-cd28 et/ou compositions anti-b7h3
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
MX2023003214A (es) * 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
AU2021374803A1 (en) * 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
MX2023008081A (es) 2021-01-11 2023-09-12 Sana Biotechnology Inc Uso de vectores virales dirigidos a cd8.
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
EP4381081A1 (fr) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Utilisation de vecteurs viraux ciblant cd4
EP4472646A1 (fr) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
US12365743B2 (en) * 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
IL314916A (en) 2022-03-07 2024-10-01 Novimmune Sa Bispecific CD28 antibodies for targeted T cell activation
EP4493592A1 (fr) 2022-03-14 2025-01-22 LamKap Bio gamma AG Anticorps anti-gpc3xcd28 et anti-gpc3xcd3 bispécifiques et leur combinaison pour la destruction ciblée de cellules malignes positives à gpc3
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
WO2023193239A1 (fr) 2022-04-08 2023-10-12 Peter Peizhi Luo Anticorps anti-cd28 et leurs procédés d'utilisation
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途
US20250368738A1 (en) 2022-07-22 2025-12-04 Philogen S.P.A Anti-cd28 antibodies
WO2024026377A1 (fr) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Procédés de transduction utilisant un vecteur viral et des inhibiteurs de facteurs de restriction antiviraux
IL318426A (en) * 2022-08-02 2025-03-01 Regeneron Pharma Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
CN117844748A (zh) * 2022-09-30 2024-04-09 北京昌平实验室 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
IL323074A (en) * 2023-03-13 2025-10-01 Regeneron Pharma Methods for treating cancer with anti-CD22 x anti-CD28 bispecific molecules
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025026356A1 (fr) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 Anticorps bispécifique ciblant un antigène associé à une tumeur et cd28, et utilisation d'un anticorps bispécifique
IL325956A (en) 2023-08-02 2026-03-01 Regeneron Pharma Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28
KR20260049559A (ko) 2023-08-02 2026-04-14 리제너론 파아마슈티컬스, 인크. 이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025085610A1 (fr) * 2023-10-18 2025-04-24 Janssen Biotech, Inc. Traitement combiné de cancers de la prostate à l'aide de deux anticorps bispécifiques
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
WO2025171124A1 (fr) * 2024-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer de la prostate avec des anticorps bispécifiques anti-psma x anti-cd3 et anticorps bispécifiques anti-psma x anti-cd28
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
WO2026078067A1 (fr) 2024-10-08 2026-04-16 Novimmune Sa Anticorps monospécifiques fcrh5 et anticorps bispécifiques fcrh5xcd28 dérivés et leur utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008529556A (ja) * 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
EP3192810A1 (fr) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Anticorps se liant au psma et leurs utilisations
WO2018014001A1 (fr) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Constructions multiples de domaines de liaison bi-spécifiques ayant une liaison à l'épitope différente pour traiter le cancer
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
US11993661B2 (en) * 2018-06-18 2024-05-28 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
MA54540A (fr) * 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
US11453721B2 (en) * 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
CA3134335A1 (fr) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Anticorps multispecifiques egfr x cd28
MX2023003214A (es) 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.

Also Published As

Publication number Publication date
KR20250156829A (ko) 2025-11-03
AU2019290198B2 (en) 2025-10-09
SG11202012729YA (en) 2021-01-28
WO2019246514A1 (fr) 2019-12-26
AU2026200069A1 (en) 2026-01-22
US11548947B2 (en) 2023-01-10
JP2021527431A (ja) 2021-10-14
US20190389951A1 (en) 2019-12-26
EP3810282A1 (fr) 2021-04-28
CN119143875A (zh) 2024-12-17
US20230272078A1 (en) 2023-08-31
JP7677796B2 (ja) 2025-05-15
MX2020013804A (es) 2021-03-31
BR112020025926A2 (pt) 2021-03-23
KR20210023982A (ko) 2021-03-04
MX419677B (es) 2025-01-14
JP2025121953A (ja) 2025-08-20
AU2019290198A1 (en) 2021-01-14
KR102875950B1 (ko) 2025-10-24
IL325874A (en) 2026-03-01
CL2020003285A1 (es) 2021-05-28
IL279354A (en) 2021-01-31
US12441800B2 (en) 2025-10-14
MY205387A (en) 2024-10-18
CN112351820B (zh) 2024-10-11
PH12020552116A1 (en) 2021-07-19
US20230303696A1 (en) 2023-09-28
CA3104098A1 (fr) 2019-12-26
IL279354B1 (en) 2026-02-01
CN112351820A (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
FR25C1029I2 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3891187A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-4-1bb et leurs utilisations
MA52771A (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3833693A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
EP3897719A4 (fr) Anticorps bispécifiques clivables par la protéase et utilisations associées
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3966252A4 (fr) Anticorps anti-cd137 humanisés et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755716A4 (fr) Anticorps anti-pd-1 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
MA55613A (fr) Anticorps anti-intégrine et leurs utilisations
EP3883969A4 (fr) Anticorps anti-pd-1 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations